Skip to main content
. 2017 May 26;8(44):75979–75988. doi: 10.18632/oncotarget.18275

Figure 4.

Figure 4

Biochemical recurrence-free survival according to GRS (- 2.0) (A) among pathologic T3 patients and (B) among pathologic T2 margin-positive patients.